OSE Immunotherapeutics Limited Company (Société anonyme)
Climate Impact & Sustainability Data (2021-01 to 2021-06, 2023)
Reporting Period: 2021-01 to 2021-06
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- Not disclosed
Environmental Achievements
- Not disclosed
Social Achievements
- Not disclosed
Governance Achievements
- Not disclosed
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Not disclosed
Environmental Challenges
- Not disclosed
Mitigation Strategies
- Not disclosed
Supply Chain Management
Supplier Audits: Not disclosed
Responsible Procurement
- Not disclosed
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Null
Certifications: Null
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Not disclosed
Reporting Period: 2023
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- Not disclosed
Environmental Achievements
- Not disclosed
Social Achievements
- Not disclosed
Governance Achievements
- Not disclosed
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Not disclosed
Environmental Challenges
- Risks linked to the development of drug candidates (including product development, clinical and preclinical phase completion, subcontractor default, dependency on programs, and immuno-therapeutic approaches).
- Risks linked to the partnership strategy (research dependency and potential conflicts with licensees).
- Risks linked to marketing (obtaining Marketing Authorization, lack of commercial success, and changes in drug reimbursement policies).
- Risks linked to capital requirements (uncertain additional funding, availability of public grants, and intangible asset valuation).
- Risks linked to intellectual property rights (patent protection, legal liability, and third-party patent rights).
- Risk linked to the control system for foreign investors in France.
- Exceptional events and litigation.
Mitigation Strategies
- Organization of management bodies and use of external expertise to optimize decision-making.
- Strict audits by regulatory agencies and the company for subcontractors.
- Implementation of a communication plan with a process for reviewing outgoing data.
- Partnership strategies, growth strategies, and acquisition of new candidates.
- Process for managing patents and the company's rights.
- Insurance policies (business and professional civil liability, professional multi-risk, cyber risk, clinical trial insurance, and managers’ liability).
- Not disclosed
Supply Chain Management
Supplier Audits: Not disclosed
Responsible Procurement
- Not disclosed
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Null
Certifications: Null
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Not disclosed